Register entry
Bio-Technology General (Israel) Ltd.
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 2
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
22 active NDC listings: 1 bulk ingredient, 1 drug for further processing. By marketing category: BULK INGREDIENT 1, DRUG FOR FURTHER PROCESSING 1.
| Dosage form | NDCs |
|---|---|
| powder, for solution | 1 |
| solution | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| bio-technology general (israel) ltd. | 2 |
Catalogue
Marketed products
2| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Pegloticase | solution | 84606-6824DRUG FOR FURTHER PROCESSING |
| - | Somatropin | powder, for solution | 84606-0824BULK INGREDIENT |
Enquiry
Common questions
- Is Bio-Technology General (Israel) Ltd. FDA approved?
- Bio-Technology General (Israel) Ltd. holds no registered establishment of its own; 2 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Bio-Technology General (Israel) Ltd. make?
- 2 products are listed under Bio-Technology General (Israel) Ltd. in the openFDA NDC Directory, most often as powder, for solution; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.